{"id":"NCT00496015","sponsor":"GlaxoSmithKline","briefTitle":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","officialTitle":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07-02","primaryCompletion":"2008-03-25","completion":"2009-02-17","firstPosted":"2007-07-04","resultsPosted":"2019-01-18","lastUpdate":"2019-01-18"},"enrollment":750,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A.","otherNames":[]},{"type":"BIOLOGICAL","name":"Infanrix hexa.","otherNames":["DTPa-HBV-IPV/Hib"]},{"type":"BIOLOGICAL","name":"Meningococcal vaccine GSK134612.","otherNames":["Mencevax™"]},{"type":"DRUG","name":"Paracetamol.","otherNames":[]}],"arms":[{"label":"Synflorix I Group","type":"EXPERIMENTAL"},{"label":"Synflorix II Group","type":"EXPERIMENTAL"},{"label":"Synflorix PRE Group","type":"EXPERIMENTAL"},{"label":"Synflorix POST Group","type":"EXPERIMENTAL"},{"label":"Mencevax + Infanrix Hexa Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of a booster dose of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically and to assess the impact of pneumococcal conjugate vaccine on pneumococcal and H. influenzae nasopharyngeal carriage compared to control group receiving meningococcal conjugate vaccine (GSK134612).\n\nThis protocol posting deals with objectives \\& outcome measures of the booster phase. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00370318).","primaryOutcome":{"measure":"Number of Subjects Reported With Core Fever (Rectal Temperature) Greater Than or Equal to (≥) the Cut-off","timeFrame":"Within 4 days (Day 0-3) after primary vaccine dose.","effectByArm":[{"arm":"Synflorix I Group","deltaMin":64,"sd":null},{"arm":"Synflorix II Group","deltaMin":14,"sd":null},{"arm":"Synflorix PRE Group","deltaMin":100,"sd":null},{"arm":"Synflorix POST Group","deltaMin":16,"sd":null},{"arm":"Mencevax + Infanrix Hexa Group","deltaMin":146,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":26},"locations":{"siteCount":10,"countries":["Czechia"]},"refs":{"pmids":["19837254","21215830"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":178},"commonTop":["Irritability","Somnolence","Pyrexia","Erythema","Pain"]}}